COVID 2019 - Influenza combination vaccine - Vivaldi Biosciences
Alternative Names: Delta-19Latest Information Update: 28 Jul 2026
At a glance
- Originator Vivaldi Biosciences
- Class COVID-19 vaccines; Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections; Influenza virus infections
Most Recent Events
- 28 Jul 2026 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Intranasal)
- 28 Jul 2026 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Intranasal)
- 01 Jul 2024 Vivaldi Biosciences plans to file an IND application for COVID-2019 and influenza virus infections (Vivaldi Biosciences pipeline, July 2024)